EWTX250117P22500
- 0.30
- 0.000.00%
Edgewise Therapeutics Newsroom
Evercore ISI Group Maintains Outperform on Edgewise Therapeutics, Raises Price Target to $50
Edgewise Therapeutics Analyst Ratings
Evercore Maintains Edgewise Therapeutics(EWTX.US) With Buy Rating, Maintains Target Price $50
EWTX Stock Rises on Upbeat Data From Rare Muscular Disorder Study
A Quick Look at Today's Ratings for Edgewise Therapeutics(EWTX.US), With a Forecast Between $50 to $50
Edgewise Therapeutics Price Target Raised to $50 From $44 at Leerink
Tesla, Micron, Broadcom, MARA Holdings And Other Big Stocks Moving Higher On Monday
Edgewise Therapeutics Shares 23% Higher on Positive Trial Results
Edgewise Therapeutics' Lead Candidate Reduces Biomarker Levels In Mid-Stage Study In Patients With Muscle Weakness Disease
Express News | Edgewise Therapeutics Inc : RBC Raises Target Price to $56 From $44
PepGen Stock Craters 35% on FDA Clinical Hold
Sector Update: Health Care Stocks Mixed Pre-Bell Monday
Sector Update: Health Care
Edgewise's Phase 2 Trial of Sevasemten to Treat Becker Muscular Dystrophy Meets Primary Endpoint; Shares Up 22% Pre-Bell
Top Premarket Gainers
Why Edgewise Therapeutics Shares Are Trading Higher By Over 26%; Here Are 20 Stocks Moving Premarket
Express News | Edgewise Therapeutics Shares up 8.6% Premarket After Co's Genetic Disorder Drug Meets Main Goal in Mid-Stage Study
Express News | Edgewise Therapeutics Inc - Sevasemten Was Well-Tolerated and No New Safety Concerns Were Observed
Express News | Edgewise Therapeutics Inc - Trial Met Primary Endpoint of Change in CK Levels
Edgewise Therapeutics Announces Positive Topline Results From the CANYON Phase 2 Trial of Sevasemten in Individuals With Becker Muscular Dystrophy (Becker)